证券代码：688139 证券简称：海尔生物 公告编号：2025-034 青岛海尔生物医疗股份有限公司 关于注销部分募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、募集资金基本情况 经上海证券交易所科创板股票上市委员会 2019 年 7 月 30 日审核同意，并经 中国证券监督管理委员会 2019 年 9 月 20 日下发《关于同意青岛海尔生物医疗股 份有限公司首次公开发行股票注册的批复》（证监许可[2019]1742 号）核准， 同意青岛海尔生物医疗股份有限公司（以下简称"公司"、"本公司"或"海尔 生物"）公开发行人民币普通股不超过 79,267,940 股，每股发行价格为人民币 15.53 元，募集资金总额为人民币 1,231,031,108.20 元，实际到账金额人民币 1,161,576,074.14 元，包括尚未划转的其他发行费用。上述募集资金于 2019 年 10 月 22 日到位，并经安永华明会计师事务所（特殊普通合伙）审验并出具了安 永华明（2019）验字第 61433766_J0 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-033 青岛海尔生物医疗股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法 承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 29 日 （二） 股东大会召开的地点：盈康一生大厦 15 层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 105 | | --- | --- | | 普通股股东人数 | 105 | | 2、出席会议的股东所持有的表决权数量 | 182,765,940 | | 普通股股东所持有表决权数量 | 182,765,940 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 58.2830 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 58.2830 | （四） 表决方式是否符 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 688,989,400.70, a year-on-year increase of 0.30% and a quarter-on-quarter increase of 37.30%[3]. - Net profit attributable to shareholders decreased by 19.88% year-on-year to CNY 110,258,240.35, while the net profit excluding non-recurring gains and losses fell by 25.38% to CNY 99,168,300.25[3]. - Total revenue for Q1 2025 reached ¥688,989,400.70, a slight increase from ¥686,909,061.52 in Q1 2024, representing a growth of approximately 0.31%[21]. - Net profit for Q1 2025 was ¥116,197,969.19, compared to ¥141,852,238.97 in Q1 2024, reflecting a decrease of approximately 18.1%[22]. - The total comprehensive income for Q1 2025 was ¥116,655,247.96, down from ¥141,864,993.51 in Q1 2024, reflecting a decrease of about 17.73%[22]. - Basic and diluted earnings per share for Q1 2025 were both CNY 0.35, down from CNY 0.44 in Q1 2024, indicating a decrease of approximately 20.45% year-over-year[23]. Cash Flow - The net cash flow from operating activities dropped significantly by 51.79% to CNY 37,219,201.54 compared to the previous year[3][13]. - Cash inflow from operating activities for Q1 2025 was CNY 580,704,504.07, compared to CNY 560,317,919.65 in Q1 2024, reflecting an increase of about 3.46%[24]. - Net cash flow from operating activities decreased to CNY 37,219,201.54 in Q1 2025, down 51.74% from CNY 77,204,996.82 in Q1 2024[24]. - The company reported a total cash outflow from operating activities of CNY 543,485,302.53 in Q1 2025, compared to CNY 483,112,922.83 in Q1 2024, reflecting an increase of about 12.49%[24]. - Cash inflow from investment activities for Q1 2025 was CNY 1,109,537,955.23, significantly higher than CNY 384,384,067.11 in Q1 2024, marking an increase of approximately 188.06%[25]. - Net cash flow from investment activities improved to CNY 82,434,530.50 in Q1 2025, compared to a negative CNY 7,529,404.95 in Q1 2024[25]. - Cash inflow from financing activities totaled CNY 194,362,611.12 in Q1 2025, a substantial increase from CNY 5,170,000.00 in Q1 2024[25]. - The net increase in cash and cash equivalents for Q1 2025 was CNY 102,689,591.57, compared to CNY 50,425,150.14 in Q1 2024, indicating a growth of approximately 103.67%[25]. - The ending balance of cash and cash equivalents as of Q1 2025 was CNY 637,393,622.25, down from CNY 1,307,071,714.34 in Q1 2024[25]. Market Performance - The life sciences segment generated revenue of CNY 354 million, up 1.06% year-on-year and 53.28% quarter-on-quarter[5]. - Domestic market revenue was CNY 482 million, down 3.35% year-on-year but up 54.98% quarter-on-quarter, indicating resilience in a challenging market[6]. - Overseas market revenue reached CNY 204 million, showing a year-on-year growth of 9.88% and a quarter-on-quarter increase of 8.99%[7]. - The market share of the company's biological safety cabinet products has risen to the second brand in the domestic market during Q1 2025[7]. Research and Development - Research and development expenses totaled CNY 80,452,189.16, representing 11.68% of operating revenue, an increase of 0.43 percentage points year-on-year[4]. - Research and development expenses for Q1 2025 were ¥80,452,189.16, compared to ¥77,257,984.27 in Q1 2024, indicating a growth of about 2.85%[21]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,793[15]. - The largest shareholder, Qingdao Haier Biomedical Co., Ltd., holds 100,591,463 shares, accounting for 31.64% of the total shares[15]. - The second largest shareholder, Qingdao Haizhi Huiying Equity Investment Management Co., Ltd., holds 32,103,659 shares, representing 10.10% of the total shares[15]. - The company has no changes in the top 10 shareholders due to securities lending activities[17]. Assets and Liabilities - Total current assets as of March 31, 2025, amount to ¥2,314,000,000, a decrease from ¥2,400,000,000 as of December 31, 2024[18]. - Cash and cash equivalents decreased to ¥831,055,160.95 from ¥901,227,075.69[18]. - Accounts receivable increased to ¥431,897,441.94 from ¥323,845,820.79, indicating a growth of approximately 33.5%[18]. - Inventory decreased to ¥303,739,515.42 from ¥334,744,974.95, a decline of about 9.3%[18]. - The company's total assets amounted to ¥5,830,440,601.44, slightly up from ¥5,787,468,795.01 in the previous year[21]. - Total liabilities decreased to ¥1,121,639,324.69 from ¥1,169,332,762.22, showing a reduction of about 4.08%[20]. - The equity attributable to shareholders increased to ¥4,456,255,374.10 from ¥4,371,550,511.01, marking an increase of approximately 1.94%[20]. Operational Conditions - The company has not reported any significant changes in operational conditions during the reporting period[17]. - The company has not disclosed any new strategies or product developments in the current reporting period[17]. - The company did not report any net profit from the merged entity prior to the merger, with previous periods also showing zero net profit[23].

北京市金杜（青岛）律师事务所 关于青岛海尔生物医疗股份有限公司 2024 年年度股东大会之 法律意见书 致：青岛海尔生物医疗股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受青岛海尔生物医疗 股份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简 称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监 督管理委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民 共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特 别行政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、 规章、规范性文件和现行有效的《青岛海尔生物医疗股份有限公司章程》（以下 简称《公司章程》）的有关规定，指派律师出席了公司于 2025 年 4 月 29 日召 开的 2024 年年度股东大会（以下简称本次股东大会），并就本次股东大会相关 事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限 于： 1. 经公司 2024 年第一次临时股东大会审议通过的《公司章程》； 2. 公司 2025 年 3 月 29 日刊登于巨潮资讯 ...

海尔生物公告，2025年第一季度营业收入6.89亿元，同比增长0.30%。净利润1.1亿元，同比下降 19.88%。 ...

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which has seen a decline of 6.84% in the past month, 2.25% in the past three months, and 3.82% year-to-date [1] - The index consists of no more than 30 listed companies in the medical field selected from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index was established with a base date of December 30, 2022, and a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huatai Medical (12.68%), United Imaging (10.07%), Aibo Medical (7.84%), Yirui Technology (6.54%), Shengxiang Biology (4.89%), Nanwei Medical (4.79%), Xinmai Medical (4.59%), Haier Biomedical (4.41%), Yahui Long (3.61%), and Bairen Medical (3.46%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100% market share [1] - In terms of industry composition, medical consumables account for 47.05%, medical devices for 31.91%, and in vitro diagnostics for 21.04% [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December each year [2] - Weight factors are adjusted in accordance with the sample adjustments, which occur at the same time as the sample adjustments [2] - Special circumstances may lead to temporary adjustments to the index, such as delisting of samples or corporate actions like mergers and acquisitions [2]

Group 1 - The core viewpoint of the news is that Haier Biomedical's stock performance and financial metrics indicate a relatively low valuation compared to the industry average, despite a decline in net profit [1][3]. - As of April 28, Haier Biomedical's closing stock price was 31.02 yuan, down 2.36%, with a rolling PE ratio of 26.90 times and a total market capitalization of 9.863 billion yuan [1]. - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Haier Biomedical at the 64th position in the industry ranking [1][3]. Group 2 - Haier Biomedical focuses on providing comprehensive digital solutions for life sciences and healthcare, targeting pharmaceutical companies, research institutions, and various healthcare users [2]. - The company's main products include low-temperature storage boxes, automated biological sample storage systems, and various laboratory automation equipment [2]. - In 2022, Haier Biomedical received several prestigious awards and certifications, enhancing its reputation in the life sciences and medical innovation sectors [2]. Group 3 - For the fiscal year 2024, Haier Biomedical reported a revenue of 2.284 billion yuan, a slight increase of 0.13% year-on-year, while net profit decreased by 9.71% to 367 million yuan [3]. - The company's gross profit margin stands at 47.99% [3]. - The stock's PE ratio is significantly lower than the industry average, indicating potential undervaluation [3].

青岛海尔生物医疗股份有限公司 2024 年年度股东大会会议材料 青岛海尔生物医疗股份有限公司 2024 年年度股东大会会议材料 2025 年 4 月 29 日 1 青岛海尔生物医疗股份有限公司 2024 年年度股东大会会议材料 青岛海尔生物医疗股份有限公司 2024 年年度股东大会会议材料 青岛海尔生物医疗股份有限公司 2024 年年度股东大会材料目录 | 青岛海尔生物医疗股份有限公司 2024 年年度股东大会会议议程 3 | | | --- | --- | | 议案一：关于审议公司 2024 年度财务决算报告的议案 | 6 | | 议案二：关于公司 2024 年年度利润分配预案的议案 | 7 | | 议案三：关于审议公司 2024 年年度募集资金存放与使用情况专项报告的议案 ... | 9 | | 议案四：关于使用部分超募资金永久补充流动资金的议案 | 10 | | 议案五：关于公司预计 2025 年度日常关联交易的议案 | 11 | | 议案六：关于续聘会计师事务所的议案 | 12 | | 议案七：关于审议公司内部控制审计报告的议案 | 13 | | 议案八：关于公司第三届董事会 2025 年董事薪酬方案 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688139 证券简称：海尔生物 公告编号：2025-032 青岛海尔生物医疗股份有限公司关于参加2024年度科创板医疗器械行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025年4月25日(星期五)下午15:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2025年04月18日（星期五）至04月24日（星期四）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱haierbiomedical@haierbiomedical.com进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 青岛海尔生物医疗股份有限公司（以下简称"公司"）已于2025年3月29日发布公司2024年年度报告，为 便于广大投资者更全面深入地了解公司2024年度经营成果、财务状况， ...